Additional Warnings For V.a.c. Veraflo™ Therapy; A�C�Ulta™ Therapy System Precautions - Acelity V.A.C.ULTA Mode D'emploi

Non-clinical testing under these same conditions produced a temperature rise of <0�4°C� MR image
quality may be compromised if the area of interest is in the same area or relatively close to the position of
the V�A�C� GranuFoam Silver® dressing�
Hyperbaric Oxygen Therapy (HBO): Do not take the V�A�C�Ulta™ Therapy Unit into a hyperbaric oxygen
chamber� The V�A�C�Ulta™ Therapy Unit is not designed for this environment, and should be considered
a fire hazard� After disconnecting the V�A�C�Ulta™ Therapy Unit, either (i) replace the V�A�C�® Dressing or
V�A�C� VeraFlo™ Therapy Dressing with another HBO compatible material during the hyperbaric treatment,
or (ii) cover the unclamped end of the V�A�C�® Tubing with dry gauze� For HBO therapy, the V�A�C�® Tubing
or V�A�C� VeraFlo™ Therapy tubing must not be clamped� Never leave a V�A�C�® Dressing in place without
active V�A�C�® Therapy for more than two hours (refer to the Keep V.A.C.® Therapy On section)�
NOTE: If using V.A.C. VeraFlo™ Therapy ensure that irrigation fluid or treatment
solutions are fully removed from the dressing prior to stopping negative pressure
wound therapy.
ADDITIONAL WARNINGS FOR V.A.C. VERAFLO™ THERAPY
Topical Wound Solutions: Topical wound solutions or suspensions may enter internal
body cavities if the wound is open to such cavities� They should not be infused into
wounds with unexplored tunnels or unexplored undermining as they may enter into
unintended cavities�
Pauses in Negative Pressure: Application of V�A�C� VeraFlo™ Therapy will result in pauses
of negative pressure wound therapy, which is not recommended on wounds requiring
continuous V�A�C�® Therapy� Do not use V�A�C� VeraFlo™ Therapy over unstable structures,
such as unstable chest wall or non-intact fascia, on patients at increased risk of bleeding,
highly exudating wounds, on flaps, grafts or wounds with acute enteric fistulae�
Bioengineered Tissue: V�A�C� VeraFlo™ Therapy is not intended for use with cellular or
acellular bioengineered tissues�
Hemostasis: Patients with difficult or fragile wound hemostasis are at increased risk of
bleeding associated with V�A�C� VeraFlo™ Therapy due to the potential for disruption of
clots or dilution of clotting factors� Do not use V�A�C� VeraFlo™ Therapy where hemostatic
agents have been used in the wound bed�
V.A.C.ULTA™ THERAPY SYSTEM PRECAUTIONS
Standard Precautions: To reduce the risk of transmission of bloodborne pathogens, apply standard
precautions for infection control with all patients, per institutional protocol, regardless of their diagnosis
or presumed infection status� In addition to gloves, use gown and goggles if exposure to body fluids is
likely�
10